Asia-Pacific Diabetes Care Devices Market has been estimated at USD 2.75 Billion in 2018 and is projected to reach USD 3.93 billion by 2023, at a CAGR of 7.41% during the forecast period from 2018 to 2023.Diabetes is a group of metabolic disorders, chronic condition which is associated with abnormally high level of sugar (glucose) in the blood. South- East Asia currently witnesses 78.3 million people affected with Diabetes which is going to reach 140.2 million by 2040. Western Pacific region witnesses 153.2 million people affected with diabetes and this number is said to reach 214.8 million by 2040.
Asia-Pacific has the highest diabetes population with the number increasing in quite an alarming rate. Due to this there is a huge demand in diabetes care devices which is primarily driving the market here. Also, the increasing healthcare costs is driving the market with increased revenues accumulated by the companies in this region. But the market growth is constrained here due to low medical literacy rate which is leading to the fall in sales of devices.
In Asia-Pacific, the diabetes care device market is segmented by type and by country. By type the market has been segmented in to Insulin delivery devices, Diabetes monitoring devices and Diabetes Control Solutions. The products in each of these segments are segregated in the following way: Diabetes Monitoring Devices (Self-blood Monitoring Devices: Blood Glucose Monitoring Devices, Test Strips, Lancets and Hemoglobin A1c Testing Kits; Continuous Glucose Monitoring Devices); Insulin Delivery Devices (Insulin Pens, Insulin Pumps, Jet Injectors and Insulin Syringes) and Diabetes Control Solutions.
Geographically, the market in Asia-Pacific region is segmented into China, India, Japan, Korea and Australia. China and India are the leading contributors in this region with large incidence of companies involved in manufacturing diabetes care devices, due to the highest prevalence of diabetes population in their regions. China has the world’s largest population with close to 1.4 billion people, followed by India with around 1.2 billion people in 2014. According to the International Diabetes Federation, China had the largest number of diabetic patients with around 96.2 million diabetic patients followed by India with around 66.8 million diabetic patients in 2014. This represents a majority of approximately 40-45% of the global diabetic population living in India and China, providing significant opportunities for the global diabetes care devices companies to invest in this region.
Roche Diagnostics, Ascensia, Abbott Laboratories, Novo Nordisk, Johnson & Johnson, Tandem and Terumo are the top companies in Asia-Pacific Diabetes Care Devices Market.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Global Diabetes Care Devices Market, by Type
5.1.1 Glucose Monitoring Devices
5.1.1.1 Self Blood Glucose Monitoring Devices
5.1.1.1.1 Glucose Meters
5.1.1.1.2 Test strips
5.1.1.1.3 Lancets
5.1.1.1.4 Hemoglobin A1c testing Kits
5.1.1.2 Continous Glucose Monitoring Devices
5.1.2 Insulin Delivery Systems
5.1.2.1 Insulin Syringes
5.1.2.2 Insulin Pens
5.1.2.3 Insulin Pumps
5.1.2.4 Jet Injectors
5.1.3 Control Solutions
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 F. Hoffmann-La Roche Ltd
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Medtronic Inc.
8.3 Johnson & Johnson
8.4 Abbott Laboratories
8.5 Becton, Dickinson and Company
8.6 Ascensia Diabetes care
8.7 Novo Nordisk A/S
8.8 Dexcom, Inc.
8.9 Insulet Corporation
8.10 Terumo Corporation
8.11 Tandem Diabetes Care, Inc
8.12 Ypsomed AG
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
